Utilizing Technology for Optimization of Pain Management and Mobilization in High Risk Cardiac Surgical ICU Patients

Sponsor
Cedars-Sinai Medical Center (Other)
Overall Status
Unknown status
CT.gov ID
NCT04146727
Collaborator
(none)
168
1
17
9.9

Study Details

Study Description

Brief Summary

The purpose of this project is to improve mobility in the perioperative period using activity trackers to augment current practice.

Delirium and poor functional status following ICU stays are intractable problems for which clear solutions do not exist. Digital health approaches have not been applied to these problems in the ICU setting and may represent a viable and unexplored intervention.

The program will involve the utilization of an activity tracker in ambulating patients. There will be two arms to the program. The first will involve the longitudinal study of ambulating lung transplant patients. Patients will be given an activity tracker at time of transplant which will continue throughout their care into their first month at home. The data will be collected to identify correlation between activity and clinical outcomes.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Early mobilization of patients, minimizing sedatives, maximizing pain control, optimizing sleep are strongly associated with decreased rates of delirium, decreased ICU length of stay, decreased hospital length of stay as well as improved functional status and quality of life at 1 year. Cardiac surgical patients that are at high risk of prolonged stay in the ICU due to the inherent nature of their disease (ie need for MCS (mechanical circulatory support) or lung transplantation) are most likely to benefit from a systematic aggressive approach to early mobilization. Technology such as activity trackers and virtual reality have been studied in general surgical populations but with limited data in the ICU and to date no studies in a cardiac surgical population. Activity trackers utilized in a multidisciplinary team to provide objective data to care teams and patients can be used to develop goal setting and patient motivation for teams, thereby improving mobility

    Overall Goal: To evaluate whether quantitative information on post procedural ambulation in mechanical device patients, cardiac surgical patients and lung transplant patients can improve care teams ability to monitor and identify patients at high risk for complications and prolonged length of stay.

    • The purpose of the research is to improve mobility in the perioperative period using Activity Trackers to augment current practice.

    • Objective quantification and improvement in activity of post cardiac surgery patients might result in improved clinical outcomes, thereby making this tool a part of routine practice.

    Patient Populations:
    1. Lung transplant patients

    2. Routine postoperative Cardiac surgical patients (elective cardiac surgical procedures including CABG and Valve replacement)

    3. Device Patients (axillary patients pre-open heart transplantation (OHT). Post MCS patients)

    Specific Aim 1: Create standardized trajectories for ambulation of study subject populations from time of index procedure to 30 days postoperatively Specific Aim 2: To determine if deviation from the standardized trajectory of postoperative ambulation predicts disposition (home, rehabilitation facility or SNF), length of stay, 30 day readmissions, intensive care unit (ICU) readmission, DVT, respiratory insufficiency (aspiration) Specific Aim 3: To determine if decline in ambulation over 48 hours for a given patient predicts outcomes including length of stay, readmission to an icu, readmission to hospital, deep vein thrombosis (DVT), respiratory insufficiency.

    The purpose of this project is to improve mobility in the perioperative period using activity trackers to augment current practice.

    Delirium and poor functional status following ICU stays are intractable problems for which clear solutions do not exist. Digital health approaches have not been applied to these problems in the ICU setting and may represent a viable and unexplored intervention.

    The program will involve the utilization of an activity tracker in ambulating patients. There will be two arms to the program. The first will involve the longitudinal study of ambulating lung transplant patients. Patients will be given an activity tracker at time of transplant which will continue throughout their care into their first month at home. The data will be collected to identify correlation between activity and clinical outcomes.

    The second part of the program will be within the intensive care unit. The daily step count will be recorded for all ambulatory patients that fall into one of the defined subject populations and have signed informed consent. Step counts will be displayed for the care teams as well as the patient. This will be utilized by team to continuously evaluate and modify physical mobility goals for the patient with earlier recognition of decreasing mobility which is associated with worse outcomes. The goals and progress for the patient will be displayed to the nursing staff and the patient which we hypothesize will increase motivation.

    Our hypothesis is that these interventions will increase mobility, decrease ICU length of stay, optimize the ICU experience, and potentially increase in 6-month functional status.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    168 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Utilizing Technology for Optimization of Pain Management and Mobilization in High Risk Cardiac Surgical ICU Patients
    Anticipated Study Start Date :
    Jan 1, 2020
    Anticipated Primary Completion Date :
    Jan 1, 2021
    Anticipated Study Completion Date :
    Jun 1, 2021

    Arms and Interventions

    Arm Intervention/Treatment
    ICU Duration

    The total study duration is determined by their length of stay in the ICU.

    Transplant through 1 month at Home

    Time from surgery through 1 month at home. Maximum duration is length of stay in the ICU plus 1 month at home.

    Outcome Measures

    Primary Outcome Measures

    1. Daily ambulation [From date of inclusion until discharge from hospital assessed up to 30 days post enrollment]

      Steps taken

    2. Length of Stay [From date of inclusion until discharge from hospital assessed up to 30 days post enrollment]

      Days until Discharge to a transitional care facility vs. home

    3. Admit again to ICU [From date of inclusion until event or 30 days post enrollment]

      Readmissions to an ICU or hospital

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:

    Patients that are at high-risk patients for one of the following interventions, will be considered for this study:

    1. Axillary impella patients awaiting transplant, advanced MCS therapy or weaning

    2. MCS patients post procedure including TAH, LVADs

    3. Lung Transplant patients

    4. Subjects > 18 years of age.

    5. Ability to provide informed consent and follow-up with protocol procedures

    Exclusion Criteria:
    1. Non-ambulatory patients

    2. Participation in an on-going protocol studying an experimental drug or device

    3. Use of a walker, cane or wheelchair at baseline

    4. Inability to wear the biosensor on the wrist

    5. Any condition or other reason that, in the opinion of the Investigator or Medical Monitor, would render the subject unsuitable for the study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Cedars-Sinai Medical Center Los Angeles California United States 90048

    Sponsors and Collaborators

    • Cedars-Sinai Medical Center

    Investigators

    • Principal Investigator: Anahat Dhillon, MD, Cedars-Sinai Medical Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Anahat Dhillon, Staff Physician II, Cedars-Sinai Medical Center
    ClinicalTrials.gov Identifier:
    NCT04146727
    Other Study ID Numbers:
    • pro000578722
    First Posted:
    Oct 31, 2019
    Last Update Posted:
    Oct 31, 2019
    Last Verified:
    Oct 1, 2019
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 31, 2019